The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Leukemia 2019 Jun 10. Epub 2019 Jun 10.

Department of Medicine A, University Hospital Münster, Münster, Germany.

Calcitonin receptor-like (CALCRL) is a G-protein-coupled neuropeptide receptor involved in the regulation of blood pressure, angiogenesis, cell proliferation, and apoptosis, and is currently emerging as a novel target for the treatment of migraine. This study characterizes the role of CALCRL in acute myeloid leukemia (AML). We analyzed CALCRL expression in collectively more than 1500 well-characterized AML patients from five international cohorts (AMLCG, HOVON, TCGA, Leucegene, and UKM) and evaluated associations with survival. In the AMLCG analytic cohort, increasing transcript levels of CALCRL were associated with decreasing complete remission rates (71.5%, 53.7%, 49.6% for low, intermediate, high CALCRL expression), 5-year overall (43.1%, 26.2%, 7.1%), and event-free survival (29.9%, 15.8%, 4.7%) (all P < 0.001). CALCRL levels remained associated with all endpoints on multivariable regression analyses. The prognostic impact was confirmed in all validation sets. Genes highly expressed in CALCRL AML were significantly enriched in leukemic stem cell signatures and CALCRL levels were positively linked to the engraftment capacity of primary patient samples in immunocompromised mice. CRISPR-Cas9-mediated knockout of CALCRL significantly impaired colony formation in human myeloid leukemia cell lines. Overall, our study demonstrates that CALCRL predicts outcome beyond existing risk factors and is a potential therapeutic target in AML.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0505-xDOI Listing
June 2019
9 Reads

Publication Analysis

Top Keywords

calcrl expression
8
myeloid leukemia
8
acute myeloid
8
calcitonin receptor-like
8
receptor-like calcrl
8
neuropeptide receptor
8
calcrl
6
intermediate high
4
leukemia aml
4
low intermediate
4
analyzed calcrl
4
calcrl acute
4
expression collectively
4
complete remission
4
aml analyzed
4
high calcrl
4
expression 5-year
4
treatment migraine
4
cohort increasing
4
target treatment
4

References

(Supplied by CrossRef)

K Kitamura et al.
Biochem Biophys Res Commun 1993

SD Brain et al.
Nature 1985

IM Larrayoz et al.
J Transl Med 2014

FA Russell et al.
Physiol Rev 2014

RB Davis et al.
JCI Insight 2017

AD Hershey et al.
N Engl J Med 2017

C Berenguer-Daize et al.
Clin Cancer Res 2013

I Kaafarani et al.
FASEB J 2009

L Ouafik et al.
Am J Pathol 2002

P Chen et al.
Clin Cancer Res 2011

Similar Publications